Risk factor
Very high price volatility
Profitability factor
Very favourable analyst view
About
Santhera Pharmaceuticals Holding AG, a specialty pharmaceutical company, together with its subsidiaries, develops and commercializes medicines for rare neuromuscular and pulmonary diseases with high unmet medical need in the European Union and internationally. The company's lead pipeline candidate includes vamorolone, which is being developed as treatments for Duchenne muscular dystrophy (DMD). Its clinical stage pipeline...
Company Valuation
Based on key historical and expected multiples, the stock is undervalued relative to its peers. In particular, the stock is undervalued on P/FCF.
Target Price
The average target price of SANN.SW is 30 and suggests 84% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to incre
Buy
Sell